Can you take Chlorotrianisene with Raloxifene?

Raloxifene has a moderate potential interaction with Cerebrovascular Insufficiency.

In studies of postmenopausal women with documented coronary heart disease or at increased risk for coronary events, an increased risk of death due to stroke was observed after treatment with raloxifene. The risk-benefit balance should be considered in women at risk for stroke, such as prior stroke or transient ischemic attack (TIA), atrial fibrillation, hypertension, or cigarette smoking.

Raloxifene has a moderate potential interaction with Heart Disease.

In studies of postmenopausal women with documented coronary heart disease or at increased risk for coronary events, an increased risk of death due to stroke was observed after treatment with raloxifene. The risk-benefit balance should be considered in women at risk for stroke, such as prior stroke or transient ischemic attack (TIA), atrial fibrillation, hypertension, or cigarette smoking.

Raloxifene has a major potential interaction with Heart Failure.

The use of raloxifene is contraindicated in patients with active or past history of venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis. In clinical trials, women treated with raloxifene had an increased risk of venous thromboembolism. A less serious event, superficial thrombophlebitis, also has been reported more frequently with raloxifene. The greatest risk for deep vein thrombosis and pulmonary embolism occurs during the first four months of treatment. Therapy with raloxifene should be considered cautiously in women at risk for thromboembolic disease for other reasons, such as congestive heart failure, superficial thrombophlebitis, and active malignancy.

Raloxifene has a moderate potential interaction with High Cholesterol.

In studies of women with a history of marked hypertriglyceridemia (>5.6 mmol/L or >500 mg/dL) in response to treatment with oral estrogen or estrogen plus progestin may develop increased levels of triglycerides when treated with raloxifene. Women with this medical history should have serum triglycerides monitored when taking raloxifene.

Raloxifene has a major potential interaction with History, Thrombotic/Thromboembolic Disorder.

The use of raloxifene is contraindicated in patients with active or past history of venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis. In clinical trials, women treated with raloxifene had an increased risk of venous thromboembolism. A less serious event, superficial thrombophlebitis, also has been reported more frequently with raloxifene. The greatest risk for deep vein thrombosis and pulmonary embolism occurs during the first four months of treatment. Therapy with raloxifene should be considered cautiously in women at risk for thromboembolic disease for other reasons, such as congestive heart failure, superficial thrombophlebitis, and active malignancy.

Raloxifene has a moderate potential interaction with Liver Disease.

Raloxifene undergoes extensive first-pass metabolism in the liver. Following administration of a single oral dose in Child-Pugh Class A patients with cirrhosis and total serum bilirubin ranging from 0.6 to 2.0 mg/dL, plasma raloxifene concentrations were 2.5 times higher than in controls. Therapy with raloxifene should be administered cautiously in patients with hepatic insufficiency, since safety and efficacy have not been evaluated. Although raloxifene is generally well tolerated, even at dosages higher than currently recommended, patients with liver disease should be monitored for occurrence of undue adverse effects during raloxifene therapy.

Raloxifene has a major potential interaction with Pulmonary Embolism.

The use of raloxifene is contraindicated in patients with active or past history of venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis. In clinical trials, women treated with raloxifene had an increased risk of venous thromboembolism. A less serious event, superficial thrombophlebitis, also has been reported more frequently with raloxifene. The greatest risk for deep vein thrombosis and pulmonary embolism occurs during the first four months of treatment. Therapy with raloxifene should be considered cautiously in women at risk for thromboembolic disease for other reasons, such as congestive heart failure, superficial thrombophlebitis, and active malignancy.

Raloxifene has a moderate potential interaction with Renal Dysfunction.

Raloxifene should be used with caution in patients with moderate or severe renal impairment.

Raloxifene has a major potential interaction with Thrombotic/Thromboembolic Disorder.

The use of raloxifene is contraindicated in patients with active or past history of venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis. In clinical trials, women treated with raloxifene had an increased risk of venous thromboembolism. A less serious event, superficial thrombophlebitis, also has been reported more frequently with raloxifene. The greatest risk for deep vein thrombosis and pulmonary embolism occurs during the first four months of treatment. Therapy with raloxifene should be considered cautiously in women at risk for thromboembolic disease for other reasons, such as congestive heart failure, superficial thrombophlebitis, and active malignancy.